Key facts
- Bayer shares have experienced a market value wipeout exceeding $60 billion since acquiring Monsanto.
- Two significant court decisions are anticipated in the coming weeks.
- A U.S. Supreme Court ruling is expected regarding claims that Roundup herbicide should have been labeled a cancer risk.
- A fairness hearing for a $7.25 billion class-action settlement to resolve current and future Roundup cancer lawsuits is also scheduled.
- Investors have expressed skepticism about the proposed settlement's effectiveness.
- The U.S. administration has indicated agreement with Bayer's legal arguments before the Supreme Court.
Bayer AG shares are at a critical juncture, with two upcoming court decisions poised to significantly impact the company's market value, which has already plummeted by over $60 billion since its acquisition of Monsanto eight years ago.
Investors are closely watching for a U.S. Supreme Court ruling on Bayer's attempt to halt tens of thousands of lawsuits alleging that Monsanto's Roundup herbicide should have carried a cancer risk warning. Concurrently, a fairness hearing is scheduled for a separate $7.25 billion class-action settlement aimed at resolving both existing and future cancer claims related to Roundup.
Earlier, Bayer shares had slumped as much as 12%, erasing previous gains, as investors expressed doubts about the proposed $7.25 billion settlement's capacity to deliver a decisive turnaround. While the agreement aims to resolve numerous product liability claims, analysts from JPMorgan noted concerns about the undisclosed number of plaintiffs required to opt in for the deal to proceed and their willingness to accept the offer.
Stephan Wulf, an analyst at Oddo BHF, cautioned that the settlement faces several legal hurdles before it can take effect, with the Supreme Court's decision adding another layer of uncertainty. However, a Bayer spokesperson conveyed confidence in a favorable Supreme Court outcome. The U.S. Solicitor General's brief indicated that President Donald Trump's administration supports Bayer's interpretation of the relevant law.
Markus Manns, a portfolio manager at Union Investment, suggested that resolving the lawsuits would free up significant management capacity for strategic initiatives, such as portfolio adjustments and faster market launches.